Eric Karas

Chief Commercial Officer

Eric Karas (Chief Commercial Officer) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in SPRY. The largest single filing was $250K of SPRY (25,000 sh × $10.00, as filed), executed Jun 12.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 1 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$250K

shares × price, as filed

Last traded

Jun 12

Filed Jun 12

Open performance→

Volume by month

Buys $0 Sells $885K

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Not on file 1 filing

Sector per market data · by filing · past 12 months

Most traded names

SPRY SPRY SPRY · 0 buys · 4 sells 4 filings

Recent filings

SPRYSALE ARS Pharmaceuticals, Inc. View filing → $250K
25,000 sh × $10.00
Exec Jun 12
Filed Jun 12 · 5:30 PM ET SPRYSALE ARS Pharmaceuticals, Inc. View filing → $255K
15,000 sh × $16.99
Exec Jul 1 2025
Filed Jul 3 2025 · 5:30 PM ET SPRYSALE ARS Pharmaceuticals, Inc. View filing → $240K
15,000 sh × $16.00
Exec Jun 18 2025
Filed Jun 20 2025 · 5:30 PM ET SPRYSALE ARS Pharmaceuticals, Inc. View filing → $140K
10,000 sh × $14.00
Exec Mar 20 2025
Filed Mar 21 2025 · 5:30 PM ET SPRYSALE ARS Pharmaceuticals, Inc. View filing → $140K
10,000 sh × $14.00
Exec Sep 18 2024
Filed Sep 19 2024 · 5:30 PM ET